Molecular Changes Associated with Acquired Resistance to Crizotinib in <i>ROS1</i> -Rearranged Non–Small Cell Lung Cancer

Abstract

Molecular changes associated with acquired crizotinib resistance in ROS1-rearranged NSCLC are heterogeneous, including ROS1 tyrosine kinase mutations, EGFR activation, and epithelial-to-mesenchymal transition.